Heart failure (HF) is a global pandemic affecting at least 26 million people worldwide and is
increasing in prevalence. HF health expenditures are considerable and will increase …

Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a
foundational therapy for patients with heart failure (HF) and reduced ejection fraction …

Despite guideline recommendations and available evidence, implementation of treatment in
heart failure (HF) is poor. The majority of patients are not prescribed drugs at target doses …

Background: Poor health-related quality of life (HRQL) is common in heart failure (HF), but
there are few data on HRQL in HF and the association between HRQL and mortality outside …

Aims To assess tolerability and optimal time point for initiation of sacubitril/valsartan in
patients stabilised after acute heart failure (AHF). Methods and results TRANSITION was a …

Aims The objectives of the present study were to describe epidemiology and outcomes in
ambulatory heart failure (HF) patients stratified by left ventricular ejection fraction (LVEF) and …

Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …

Abstract Aims The European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐
HF‐LT‐R) was set up with the aim of describing the clinical epidemiology and the 1‐year …

Aims Use and dosing of guideline‐directed medical therapy (GDMT) in patients with heart
failure (HF) have been shown to be suboptimal. Among new users of GDMT in HF, we …

Background We compared the angiotensin receptor–neprilysin inhibitor LCZ696 with
enalapril in patients who had heart failure with a reduced ejection fraction. In previous …